(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 8.92% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Exagen's revenue in 2026 is $71,122,000.On average, 9 Wall Street analysts forecast XGN's revenue for 2026 to be $1,807,815,923, with the lowest XGN revenue forecast at $1,744,951,168, and the highest XGN revenue forecast at $1,900,114,464. On average, 9 Wall Street analysts forecast XGN's revenue for 2027 to be $1,990,959,486, with the lowest XGN revenue forecast at $1,899,266,578, and the highest XGN revenue forecast at $2,098,519,991.
In 2028, XGN is forecast to generate $2,250,194,838 in revenue, with the lowest revenue forecast at $2,148,545,316 and the highest revenue forecast at $2,370,691,675.